Evidence-based guide to sirolimus overdose recognition, toxicity management, and clinical recovery. Covers accidental excess dosing in transplant and off-label longevity contexts with FDA and PubMed-cited protocols.
Sirolimus has three FDA boxed warnings for infection, cancer, and mortality risk. Low-dose use still causes ulcers, dyslipidemia, and cytopenias.
Evidence-based guide to storing rapamycin (sirolimus) correctly, including temperature requirements, light sensitivity, compounded formulation stability, and shelf-life data from FDA labeling and pharmacokinetic studies.
Evidence-based protocols for switching between rapamycin (sirolimus) and other mTOR inhibitors or immunosuppressants, including everolimus, tacrolimus, and off-label longevity regimens.
A comprehensive review of FDA label changes for alprostadil (Caverject, MUSE, Edex) from 2020 through 2026, covering safety revisions, post-market surveillance data, and clinical guidance for prescribers.
A complete timeline of AndroGel (testosterone gel 1%) FDA label revisions from 2020 through 2026, covering cardiovascular warnings, REMS modifications, transfer risk language, and post-market surveillance findings.
A clinical review of AndroGel's regulatory history, patent disputes, Paragraph IV litigation, FDA label changes, and cardiovascular safety controversies from approval through post-market surveillance.
AOD-9604 has never received FDA approval. Review the full regulatory timeline, failed clinical trials, FDA compounding restrictions, and what this means for patients considering this peptide.
An evidence-based review of AOD-9604 (HGH fragment 176-191) safety signals in the FDA Adverse Event Reporting System, regulatory status, and what clinicians should know about post-market surveillance for this compounded peptide.
How the FDA and EMA differ in their regulatory handling of BPC-157 pentadecapeptide, including compounding status, clinical trial requirements, and safety oversight.
No new black box warning, but tadalafil's label added stronger hearing loss and NAION warnings, revised renal dosing, and SGLT2 interaction data.
Complete history of Cialis (tadalafil) legal battles, patent disputes, FDA approval milestones, and regulatory actions from 2003 through generic entry.
CJC-1295 (modified GRF 1-29) has never received FDA or EMA approval. Learn its current regulatory classification, compounding pharmacy status, and safety profile across major jurisdictions.
A clinical review of Trulicity's regulatory timeline, patent disputes, Paragraph IV litigation, and post-market safety actions that shape dulaglutide access in 2026.
A clinical review of dutasteride's regulatory history, current FDA label, post-market safety surveillance, and emerging next-generation 5-alpha reductase inhibitor candidates in development.
A detailed review of enclomiphene citrate's current FDA approval status, compounding legality under 503A and 503B, safety considerations, and what the regulatory picture means for patients and prescribers.
A detailed comparison of how the FDA and EMA have handled enclomiphene citrate, including its failed NDA, compounding pharmacy access, and current regulatory status for male hypogonadism.
A clinical review of enclomiphene citrate's regulatory trajectory, FDA approval status, phase III trial data, compounding pharmacy access, and emerging next-generation SERM alternatives for male hypogonadism.
Epitalon (Ala-Glu-Asp-Gly) has no FDA or EMA approval. Learn the current regulatory classification in the US, EU, Russia, Australia, and other markets, plus what the science actually shows.
Epitalon (epithalon) has no FDA approval, no active U.S. patent protection, and no completed phase III trials. This article covers the peptide's regulatory status, legal gray areas, and what the clinical evidence actually supports.
A clinical review of finasteride safety signals in the FDA Adverse Event Reporting System (FAERS), including sexual dysfunction, depression, and suicidality reports that prompted label revisions.
A cautious, source-checked look at how the FDA label and REMS program for Addyi (flibanserin) changed between 2020 and 2026, including the alcohol-warning revision and the 2023 REMS modification, with a note on which claims still need primary-source verification.
A clinician-focused review of GHK-Cu (copper tripeptide) regulatory status worldwide, including FDA compounding guidance, EMA classification, and country-by-country legal frameworks for prescribing and importing GHK-Cu.
Ipamorelin has never received FDA approval. Review the full regulatory timeline from preclinical development through compounding pharmacy access, clinical trial history, and current FDA enforcement posture.
Complete regulatory timeline of isotretinoin from its 1982 FDA approval through iPLEDGE implementation, generic entry, and ongoing post-market safety surveillance.
A detailed review of isotretinoin (Accutane) safety signals reported to the FDA Adverse Event Reporting System (FAERS), covering psychiatric events, IBD associations, teratogenicity monitoring through iPLEDGE, and what the post-market surveillance data mean for prescribers and patients.
Low-dose naltrexone (LDN) is not FDA-approved at doses below 50 mg. Learn how 503A compounding pharmacies legally prepare LDN, current regulatory status, and the clinical evidence behind off-label prescribing.
A clinical review of low-dose naltrexone (LDN) regulatory status from 2020 through 2026, covering FDA-approved labeling for naltrexone 50 mg, compounding pharmacy oversight under 503A/503B, and emerging safety and efficacy data.
The FDA metformin label recommends measuring vitamin B12 at baseline and periodically, typically every 1 to 2 years, especially with anemia or neuropathy.
MK-677 (ibutamoren) has never received FDA approval and carries no official drug label. This article covers the 2020-2026 regulatory timeline, FDA enforcement actions, safety data, and what clinicians and patients should know.
A comprehensive review of MK-677 (ibutamoren) regulatory status, FDA history, patent disputes, and legal barriers preventing clinical approval of this growth hormone secretagogue.
MOTS-c has no FDA approval and remains an investigational mitochondrial peptide worldwide. Learn its regulatory classification in the US, EU, Australia, and Asia, plus the clinical evidence behind ongoing research.
MOTS-c has no FDA approval and no drug label. This article covers the full regulatory timeline from 2020 to 2026, including FDA peptide enforcement actions, research milestones, and safety data for this mitochondrial-derived peptide.
MOTS-c remains unapproved by the FDA with no IND-stage clinical trials in humans. This article covers the patent disputes, regulatory classification questions, and safety concerns surrounding this mitochondrial-derived peptide.
A clinical review of Mounjaro (tirzepatide) legal battles, patent disputes, FDA approval timeline, label updates, and post-market safety surveillance.
A clinical and regulatory guide to oral minoxidil compounding legality, covering FDA approval history, 503A and 503B pharmacy pathways, Loniten labeling, off-label prescribing for hair loss, and safety data.
A clinical comparison of how the FDA and EMA regulate oral minoxidil for hair loss, including approval history, labeling, off-label prescribing trends, and safety monitoring requirements.
A comprehensive review of oral minoxidil (low-dose) label updates from 2020 through 2026, covering FDA safety communications, off-label dermatologic use, cardiovascular monitoring requirements, and emerging clinical data.
A clinical review of FDA Adverse Event Reporting System (FAERS) data on low-dose oral minoxidil, including cardiovascular signals, pericardial effusion reports, and how prescribers should interpret real-world pharmacovigilance findings.
A clinical review of Ozempic (semaglutide) regulatory history, current FDA label, post-market safety surveillance, and the next-generation GLP-1 pipeline from Novo Nordisk and competitors.
A clinical review of Ozempic (semaglutide) FDA Adverse Event Reporting System signals, label updates, and post-market safety data through 2026.
A complete review of bremelanotide (Vyleesi) regulatory approvals, FDA labeling, global scheduling, and post-market safety data for hypoactive sexual desire disorder in premenopausal women.
A comprehensive review of FDA label changes for PT-141 (bremelanotide, Vyleesi) from initial approval through 2026, including safety updates, boxed warning revisions, and post-market surveillance findings.
A clinical breakdown of rapamycin (sirolimus) compounding regulations, FDA approval history, label indications, and what patients need to know about legally obtaining compounded sirolimus for off-label use.
How the FDA and EMA each regulate generic sildenafil, from bioequivalence standards and labeling differences to post-market surveillance frameworks. Evidence-based comparison for clinicians and patients.
A comprehensive regulatory guide to generic sildenafil covering FDA approval history, EMA authorization, global OTC reclassification, label requirements, and post-market safety surveillance data.
A clinical overview of generic sildenafil's regulatory history, current FDA-approved formulations, pipeline developments, and next-generation delivery systems for erectile dysfunction and pulmonary arterial hypertension.
A detailed review of FDA Adverse Event Reporting System (FAERS) data for generic sildenafil 20-100 mg, covering the most reported safety signals, serious adverse events, and what the post-market record means for prescribers and patients.
How the FDA and European regulators differ on spironolactone for acne, why neither has granted a formal indication, and what the evidence says about off-label prescribing.
A comprehensive review of spironolactone's regulatory status worldwide, including FDA approval history, off-label dermatologic use, EMA classification, and post-market safety surveillance data.
A clinical review of FDA label changes to spironolactone between 2020 and 2026, with specific focus on off-label acne use, safety warnings, and post-market surveillance findings.
A comprehensive review of tadalafil generic regulatory approvals worldwide, including FDA status, EMA authorization, safety labeling, and post-market surveillance data across major markets.
A detailed review of every FDA label update for generic tadalafil from 2020 through 2026, including revised cardiovascular warnings, NAION language, nitrate contraindications, and post-market safety signals.
A clinical review of tadalafil generic approvals, FDA regulatory history, current pipeline developments, and emerging next-gen formulations for erectile dysfunction and BPH.
A guide to TB-500 (thymosin beta-4 fragment) regulatory status worldwide, including FDA classification, compounding pharmacy access, WADA prohibitions, and country-by-country legal standing.
How the FDA and EMA differ in their approval, labeling, and post-market surveillance of testosterone cypionate for hypogonadism and testosterone replacement therapy.
A complete timeline of FDA label updates for testosterone cypionate from 2020 through 2026, including cardiovascular warnings, abuse potential language, polycythemia alerts, and the impact of the TRAVERSE trial on prescribing.
A clinical review of testosterone cypionate's regulatory history, FDA label updates, post-market safety data from TRAVERSE, and the next-generation testosterone delivery systems in development.
A detailed review of testosterone enanthate's regulatory approvals, labeling requirements, and post-market safety monitoring across the FDA, EMA, TGA, and other global agencies.
Current legal status of compounded thymosin alpha-1 (thymalfasin) in the United States, including FDA classification, 503A pharmacy rules, and patient access pathways.